176 related articles for article (PubMed ID: 27357023)
1. Efficient [(18)F]AlF Radiolabeling of ZHER3:8698 Affibody Molecule for Imaging of HER3 Positive Tumors.
Da Pieve C; Allott L; Martins CD; Vardon A; Ciobota DM; Kramer-Marek G; Smith G
Bioconjug Chem; 2016 Aug; 27(8):1839-49. PubMed ID: 27357023
[TBL] [Abstract][Full Text] [Related]
2. Benefit of Later-Time-Point PET Imaging of HER3 Expression Using Optimized Radiocobalt-Labeled Affibody Molecules.
Rinne SS; Dahlsson Leitao C; Saleh-Nihad Z; Mitran B; Tolmachev V; Ståhl S; Löfblom J; Orlova A
Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32183096
[TBL] [Abstract][Full Text] [Related]
3. Three methods for 18F labeling of the HER2-binding affibody molecule Z(HER2:2891) including preclinical assessment.
Glaser M; Iveson P; Hoppmann S; Indrevoll B; Wilson A; Arukwe J; Danikas A; Bhalla R; Hiscock D
J Nucl Med; 2013 Nov; 54(11):1981-8. PubMed ID: 24115530
[TBL] [Abstract][Full Text] [Related]
4. Increase in negative charge of
Rinne SS; Dahlsson Leitao C; Gentry J; Mitran B; Abouzayed A; Tolmachev V; Ståhl S; Löfblom J; Orlova A
Sci Rep; 2019 Nov; 9(1):17710. PubMed ID: 31776413
[TBL] [Abstract][Full Text] [Related]
5. Improved stability of a novel fluorine-18 labeled TCO analogue for pretargeted PET imaging.
Ruivo E; Adhikari K; Elvas F; Fissers J; Vangestel C; Staelens S; Stroobants S; Van der Veken P; Wyffels L; Augustyns K
Nucl Med Biol; 2019; 76-77():36-42. PubMed ID: 31707309
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of a radiocobalt-labelled affibody molecule for imaging of human epidermal growth factor receptor 3 expression.
Rosestedt M; Andersson KG; Mitran B; Rinne SS; Tolmachev V; Löfblom J; Orlova A; Ståhl S
Int J Oncol; 2017 Dec; 51(6):1765-1774. PubMed ID: 29039474
[TBL] [Abstract][Full Text] [Related]
7. Imaging of human epidermal growth factor receptor type 2 expression with 18F-labeled affibody molecule ZHER2:2395 in a mouse model for ovarian cancer.
Heskamp S; Laverman P; Rosik D; Boschetti F; van der Graaf WT; Oyen WJ; van Laarhoven HW; Tolmachev V; Boerman OC
J Nucl Med; 2012 Jan; 53(1):146-53. PubMed ID: 22173842
[TBL] [Abstract][Full Text] [Related]
8. First (18)F-labeled ligand for PET imaging of uPAR: in vivo studies in human prostate cancer xenografts.
Persson M; Liu H; Madsen J; Cheng Z; Kjaer A
Nucl Med Biol; 2013 Jul; 40(5):618-24. PubMed ID: 23602763
[TBL] [Abstract][Full Text] [Related]
9. An Efficient Method for Labeling Single Domain Antibody Fragments with
Zhou Z; Devoogdt N; Zalutsky MR; Vaidyanathan G
Bioconjug Chem; 2018 Dec; 29(12):4090-4103. PubMed ID: 30384599
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and Evaluation of [
Huang J; Bai L; Shi D; Jiang W; Chen P; Dong Y; Zhang X; Peng J; Hou J; Lu Y; Huang X; Tang G; Huang S
Mol Pharm; 2024 May; 21(5):2425-2434. PubMed ID: 38554143
[TBL] [Abstract][Full Text] [Related]
11. A Comprehensive Review of Non-Covalent Radiofluorination Approaches Using Aluminum [
Fersing C; Bouhlel A; Cantelli C; Garrigue P; Lisowski V; Guillet B
Molecules; 2019 Aug; 24(16):. PubMed ID: 31394799
[TBL] [Abstract][Full Text] [Related]
12. In vitro and in vivo evaluation of the effects of aluminum [¹⁸F]fluoride radiolabeling on an integrin αvβ₆-specific peptide.
Hausner SH; Bauer N; Sutcliffe JL
Nucl Med Biol; 2014 Jan; 41(1):43-50. PubMed ID: 24267053
[TBL] [Abstract][Full Text] [Related]
13. Comparison of renal clearance of [
Liu J; Guo X; Wen L; Wang L; Liu F; Song G; Zhu H; Zhou N; Yang Z
Eur J Nucl Med Mol Imaging; 2023 Jul; 50(9):2775-2786. PubMed ID: 37093312
[TBL] [Abstract][Full Text] [Related]
14. HER3-Mediated Resistance to Hsp90 Inhibition Detected in Breast Cancer Xenografts by Affibody-Based PET Imaging.
Martins CD; Da Pieve C; Burley TA; Smith R; Ciobota DM; Allott L; Harrington KJ; Oyen WJG; Smith G; Kramer-Marek G
Clin Cancer Res; 2018 Apr; 24(8):1853-1865. PubMed ID: 29437790
[No Abstract] [Full Text] [Related]
15. Influence of Residualizing Properties of the Radiolabel on Radionuclide Molecular Imaging of HER3 Using Affibody Molecules.
Rinne SS; Xu T; Dahlsson Leitao C; Ståhl S; Löfblom J; Orlova A; Tolmachev V; Vorobyeva A
Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32075258
[TBL] [Abstract][Full Text] [Related]
16. Al[
Alonso Martinez LM; Harel F; Nguyen QT; Létourneau M; D'Oliviera-Sousa C; Meloche B; Finnerty V; Fournier A; Dupuis J; DaSilva JN
Nucl Med Biol; 2018 Dec; 67():36-42. PubMed ID: 30388434
[TBL] [Abstract][Full Text] [Related]
17. Anti-CEA antibody fragments labeled with [(18)F]AlF for PET imaging of CEA-expressing tumors.
Lütje S; Franssen GM; Sharkey RM; Laverman P; Rossi EA; Goldenberg DM; Oyen WJ; Boerman OC; McBride WJ
Bioconjug Chem; 2014 Feb; 25(2):335-41. PubMed ID: 24382090
[TBL] [Abstract][Full Text] [Related]
18. Thiol-Reactive PODS-Bearing Bifunctional Chelators for the Development of EGFR-Targeting [
Da Pieve C; Makarem A; Turnock S; Maczynska J; Smith G; Kramer-Marek G
Molecules; 2020 Mar; 25(7):. PubMed ID: 32235296
[TBL] [Abstract][Full Text] [Related]
19. Comparative evaluation of 111In-labeled NOTA‑conjugated affibody molecules for visualization of HER3 expression in malignant tumors.
Andersson KG; Rosestedt M; Varasteh Z; Malm M; Sandström M; Tolmachev V; Löfblom J; Ståhl S; Orlova A
Oncol Rep; 2015 Aug; 34(2):1042-8. PubMed ID: 26059265
[TBL] [Abstract][Full Text] [Related]
20. Automated Synthesis and Preclinical Evaluation of Optimized Integrin α6-Targeted Positron Emission Tomography Imaging of Pancreatic Cancer.
Chen L; Fu H; He H; Lou K; Li Q; Ye J; Feng G; Yu C
Mol Pharm; 2023 Aug; 20(8):4277-4284. PubMed ID: 37463487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
